featured
Patients With Persistent Mild Psoriasis After Treatment With Ustekinumab Achieve Greater Improvements in Outcomes After Switching to Guselkumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Acta Dermato-Venereologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial
Acta Derm Venereol 2024 Sep 05;104(xx)adv41053, E Errichetti, P Wolf, S Khattri, P Gorecki, M Miller, J Jiang, C Han, B KirbyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.